Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.40 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.40 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CTSA | P10619 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1678301 | 0.82 | ACHE (0.41) | FFAR1L3MBTL1ACHEALDH1A1STAT3 | |
| SCHEMBL237090 | 0.81 | FFAR1 (0.70) | FFAR1ALDH1A1 | |
| SCHEMBL1149768 | 0.81 | FFAR1 (0.70) | FFAR1ALDH1A1 | |
| SCHEMBL237091 | 0.81 | FFAR1 (0.70) | FFAR1ALDH1A1 | |
| SCHEMBL27498071 | 0.81 | BCHE (0.43) | FFAR1MMP12MMP13NAPRTGAA | |
| SCHEMBL5670253 | 0.80 | GAA (0.39) | FFAR1L3MBTL1ACHEKCNA5GAA | |
| SCHEMBL28810021 | 0.79 | ACHE (0.39) | FFAR1L3MBTL1ACHEKCNA5GAA | |
| Hydrochloric Acid SCHEMBL2005345 | 0.79 | FFAR1 (0.68) | FFAR1ALDH1A1 | |
| SCHEMBL2899426 | 0.79 | FFAR1 (0.68) | FFAR1ALDH1A1 | |
| SCHEMBL11332403 | 0.79 | FFAR1 (0.62) | FFAR1ACHEALDH1A1TSHRSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658667-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | Merck Sharp & Dohme LLC (US) | 2025-12-10 | — | — | EP | disclosed |
| WO-2024163691-A1 | CYCLIC PEPTIDES FOR INHIBITING TNF RECEPTOR 1 ACTIVITY | MERCK SHARP & DOHME LLC (US) | 2024-08-08 | — | — | WO | disclosed |
| US-7923461-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-04-12 | — | — | US | disclosed |
| EP-1568692-B1 | (Pyridinyl)alkyl-amides or -ureas as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2010-09-15 | — | — | EP | disclosed |
| US-7741346-B2 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-06-22 | — | — | US | disclosed |
| US-20100016380-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-1743885-B1 | 1-[(adamantyl)alkyl]-3-[(pyridinyl)alkyl]urea compounds as TNF-.alpha inhibitors useful for autoimmune diseases | SANTEN PHARMACEUTICAL CO LTD (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-7491739-B2 | TNF-α production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-02-17 | — | — | US | disclosed |
| US-20080182881-A1 | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL, CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| US-20080161270-A1 | Angiogenesis inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2008-07-03 | — | — | US | disclosed |
| CN-1590375-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1457205-A1 | ANGIOGENESIS INHIBITOR | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-09-15 | — | — | EP | disclosed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| CN-1440401-A | Amino substituted dibenzothiophene derivatives for treatmnt of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2003-09-03 | — | — | CN | disclosed |
| CN-1432000-A | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | CN | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1278739-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | AstraZeneca AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001085714-A1 | AMINO SUBSTITUTED DIBENZOTHIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS MEDIATED BY THE NP Y5 RECEPTOR | ASTRAZENECA AB (SE) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182881-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | FFAR1 36/4885L3MBTL1 3932/4885MMP12 1531/4885 |
| US-20080161270-A1 | Angiogenesis inhibitors | FLT4, KDR, FLT1 | FFAR1 265/4885L3MBTL1 3120/4885MMP12 2477/4885 |
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | FFAR1 283/4885L3MBTL1 3041/4885MMP12 2449/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | FFAR1 54/4885L3MBTL1 4272/4885MMP12 1284/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | FFAR1 743/4885L3MBTL1 1377/4885MMP12 4464/4885 |
| US-20100016380-A1 | TNF-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | FFAR1 222/4885L3MBTL1 2871/4885MMP12 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.